Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:David-Alexandre_Gros
|
| gptkbp:focusesOn |
immunology
organ transplantation neurodegenerative diseases |
| gptkbp:formerName |
gptkb:Anelixis_Therapeutics
|
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
Irvine, California, United States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eledon Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:product |
gptkb:AT-1501
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockSymbol |
gptkb:ELDN
|
| gptkbp:website |
https://eledon.com
|
| gptkbp:bfsParent |
gptkb:Novus_Therapeutics
|
| gptkbp:bfsLayer |
7
|